Detalles de la búsqueda
1.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Lancet Oncol
; 19(6): 825-833, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752180
2.
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
Eur Urol
; 85(3): 217-226, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37891072
3.
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.
Eur Urol Focus
; 7(2): 234-237, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33172774
4.
Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors.
J Nucl Med
; 61(7): 1030-1036, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31806772
5.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 61(6): 857-865, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732676
6.
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
J Nucl Med
; 60(4): 517-523, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30291192
Resultados
1 -
6
de 6
1
Próxima >
>>